Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01321437 · ClinicalTrials.gov registry record · Phase 2
Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma
A Phase 2 study, sponsored by University of California, Irvine.
- Completed
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT01321437: Completed Phase 2 study, sponsored by University of California, Irvine.
NCT01321437 is a Phase 2 study that has completed, run by University of California, Irvine. The registered enrollment target is 11 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01321437, a Phase 2 study, has completed, sponsored by University of California, Irvine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of this research study is to determine the efficacy of Axitinib in treating individuals with Stage III melanoma.
Primary Outcome
The response rate (CR or PR according to Response Evaluation Criteria in Solid Tumors (RECIST) will be provided with an exact 95% 2-sided confidence interval calculated using a method based on the F distribution.
Interventions
- OTHER laboratory biomarker analysis
- DRUG Axitinib
- PROCEDURE therapeutic conventional surgery
- OTHER pharmacological study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2011-12 |
| Est. Completion | 2016-12 |
| Phase | Phase 2 |
What the finished NCT01321437 record still lists
NCT01321437 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT01321437 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01321437 about?
NCT01321437 is a clinical study titled "Study of the Anti-Angiogenesis Agent Axitinib in Patients With Stage III Malignant Melanoma". The purpose of this research study is to determine the efficacy of Axitinib in treating individuals with Stage III melanoma.
What is the current status of trial NCT01321437?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2011-12. Estimated completion is 2016-12.
What interventions are being tested in trial NCT01321437?
The interventions under investigation include: laboratory biomarker analysis (OTHER), Axitinib (DRUG), therapeutic conventional surgery (PROCEDURE), pharmacological study (OTHER).
Who is sponsoring clinical trial NCT01321437?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01321437's enrollment target sits among peer trials
11 1967th of 2000 higher than 33 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia